Structured abstract
Background Surgical resection of motor eloquent tumors poses the risk of causing postoperative motor deficits which leads to reduced quality of life in these patients. Currently, rehabilitative procedures are limited with physical therapy being the main treatment option.
Objective The present study investigated the efficacy of repetitive navigated transcranial magnetic stimulation (rTMS) for treatment of motor deficits after supratentorial tumor resection.
Methods This randomised, double-blind, sham-controlled trial recruited patients with a worsening of upper extremity motor function after tumor resection. They were randomly assigned to receive rTMS treatment (1Hz, 110% RMT, 15 minutes, 7 days) or sham stimulation to the motor cortex contralateral to the injury followed by physical therapy. Motor and neurological function as well as quality of life were assessed directly after the intervention, one month and three months postoperatively.
Results Thirty patients were recruited for this study. There was no significant difference between both groups in the primary outcome, the Fugl Meyer score three months postoperatively (Group difference [95%-CI]: 5.05 [-16.0; 26.1]; p=0.631). Patients in the rTMS group presented with better hand motor function (BMRC scores) one month postoperatively. Additionally, a subgroup of patients with motor eloquent ischemia showed lower NIHSS scores at all timepoints.
Conclusion Low-frequency rTMS facilitated the recovery process stimulated hand muscles, but with limited generalization to other functional deficits. Long-term motor deficits were not impacted by rTMS. Due to the reduced life expectancy in this patient group a shortened recovery duration of functional deficits can still be of high clinical significance.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
DRKS00010043
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors acknowledge the support of the Cluster of Excellence Matters of Activity. Image Space Material funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germanys Excellence Strategy EXC 2025 (390648296). Dr. Rosenstock is participant in the BIH Charite Digital Clinician Scientist Program funded by the Charite Universitaetsmedizin Berlin, and the Berlin Institute of Health at Charite (BIH).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics committee of the Charite - Universitaetsmedizin Berlin gave the ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Declarations of interest: none
Data Availability
Data produced in the present study cannot be shared due to data protection restrictions.
